Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PARP Inhibitor in Combination With CDK4/6 Inhibitor and Endocrine Therapy as the First-line Therapy for HR+/ HER2-Advanced Breast Cancer

NCT06612814 is registered in ClinicalTrials.gov with Zhimin Shao as lead sponsor.

NCT NCT06612814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06612814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PARP Inhibitor in Combination With CDK4/6 Inhibitor and Endocrine Therapy as the First-line Therapy for HR+/ HER2-Advanced Breast Cancer
Lead sponsor
Zhimin Shao
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 1, 2024
Completion date
April 30, 2028
Enrollment
307 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic